- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | 1 | ASX | ||
| Mi | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| Di | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| Mo | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 15.12. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 15.12. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 11.12. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 11.12. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 10.12. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 09.12. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 09.12. | VITA LIFE SCIENCES LIMITED: Profit Guidance | 1 | ASX | ||
| 08.12. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 04.12. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 03.12. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 03.12. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 02.12. | VITA LIFE SCIENCES LIMITED: Daily share buy-back notice - Appendix 3E | - | ASX | ||
| 01.12. | VITA LIFE SCIENCES LIMITED: Daily share buy-back notice - Appendix 3E | - | ASX | ||
| 01.12. | VITA LIFE SCIENCES LIMITED: Daily share buy-back notice - Appendix 3E | - | ASX | ||
| 27.11. | VITA LIFE SCIENCES LIMITED: Daily share buy-back notice - Appendix 3E | - | ASX | ||
| 26.11. | VITA LIFE SCIENCES LIMITED: Daily share buy-back notice - Appendix 3E | - | ASX |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 7,500 | -0,86 % | Multi-Bagger entdeckt!: Der europäische Cannabissektor wird in den nächsten Jahren auf 24 Mrd. $ explodieren - diese Aktie profitiert! | ||
| INDIVA | 0,016 | 0,00 % | SNDL Inc.: SNDL Emerges as Canada's Leading Producer of Edibles with Indiva Acquisition | CALGARY, AB, Nov. 4, 2024 /CNW/ - SNDL Inc. (Nasdaq: SNDL) ("SNDL" or the "Company") announced today that, in the context of Indiva Limited's ("Indiva" and together... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 227,10 | -3,53 % | Alnylam Presents New Phase 1 Results For Next-Gen RNAi Therapy Nucresiran In ATTR Amyloidosis | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) has shared new findings from its Phase 1 study of nucresiran (previously known as ALN-TTRsc04), a next-generation RNAi therapy being... ► Artikel lesen | |
| CASSAVA SCIENCES | 2,249 | -0,40 % | XFRA PX91: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,874 | -1,41 % | Nektar's NKTR-255 After CD19 CAR-T Therapy Enhances Complete Response In R/R Large B-Cell Lymphoma | WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) announced results of its Phase 2 proof-of-concept study, which evaluated NKTR-255 as an adjuvant treatment to enhance complete response rate... ► Artikel lesen | |
| ADASTRA | 0,149 | -42,25 % | Adastra Holdings Ltd.: Adastra Holdings Announces Annual General Meeting | Langley, British Columbia--(Newsfile Corp. - December 10, 2024) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) ("Adastra" or the "Company"), a leader in cannabis processing and production, is pleased... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 16,125 | -0,37 % | Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview | SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.
"The success of Acadia's two growing... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 0,875 | +0,81 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia | - Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis - - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,330 | -0,29 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan | CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc: Molecule amends, settles, converts debentures | ||
| NUMINUS WELLNESS | 0,024 | -15,73 % | Numinus Wellness Inc: Numinus Wellness closes sale of five Wellness Clinics | ||
| OPUS GENETICS | 1,028 | +7,76 % | Opus Genetics, Inc.: Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy | Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| ZELIRA THERAPEUTICS | 0,366 | -1,61 % | ZELIRA THERAPEUTICS LIMITED: Change of Director's Interest Notice | ||
| SOLIGENIX | 2,980 | -3,25 % | SOLIGENIX, INC.: Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 51,00 | -0,97 % | ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Sells 7,500 Shares |
VITA LIFE SCIENCES LIMITED gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.
